This report analyzes the worldwide markets for RNA Interference (RNAi) in US$ Million by the following application areas: Drug Discovery and Target Validation, Reagents, and siRNA Synthesis. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. The report profiles 135 companies including many key and niche players such as Alnylam Pharmaceuticals, Inc., Benitec Limited, Bioneer Corp., Calando Pharmaceuticals, Inc., Cenix BioScience GmbH, Devgen NV, Dharmacon, Inc., Dicerna Pharmaceuticals, Inc., Exiqon A/S, Genesis Research & Development Corporation Limited, Halo-Bio RNAi Therapeutics, Inc., Marina Biotech, Inc., OPKO Health, Inc., Polyplus-transfection SA, Quark Pharmaceuticals, Inc., Galena Biopharma, Sigma-Aldrich Co., Silence Therapeutics, and Tekmira Pharmaceuticals Corp. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.
Table of Contents
Table of Contents
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study
Product Segments
Drug Discovery and Target Validation
Reagents
SiRNA Synthesis
II. EXECUTIVE SUMMARY
1. INDUSTRY OUTLOOK
RNA Interference: A Historic Perspective
RNAi Time Line
2. INDUSTRY OVERVIEW
Leading Regional Markets
High-throughput Screening: A Promising Application for RNA Interference
Growth Drivers
3. MARKET OUTLOOK
RNA Interference: A Potential Oligonucleotide Technology
A Review of Select Classes of Oligonucleotides Competing with siRNA
Oligonucleotide Market Sustains Recession
Select RNAi-based Therapeutics in the Pipeline
RNAi: A Leading Research Tool in Gene-Silencing
RNAi-based Drugs to Emerge as a New Class of Therapeutics
RNAi-based Therapeutics to Drive the Growth of RNAi Market
Statistics on Select Diseases
Cancer
Table 1: Global Cancer Incidence by Region: 2009 (includes corresponding Graph/Chart)
Table 2: Global Cancer Incidence by Country: 2009 (includes corresponding Graph/Chart)
Table 3: Global Cancer Incidence by Income Group: 2009 (includes corresponding Graph/Chart)
Table 4: Global Cancer Related Deaths in Male Population by Site: 2007 (includes corresponding Graph/Chart)
Table 5: Global Cancer Related Deaths in Female Population by Site: 2007(includes corresponding Graph/Chart)
Cardiovascular Diseases
Table 6: Global Coronary Heart Disease Prevalence by Region (includes corresponding Graph/Chart)
Table 7: Deaths Due to Major Cardiovascular Diseases in the US: Percentage Share Breakdown by Disease Type (includes corresponding Graph/Chart)
Huntington's Disease (HD)
Diabetic Retinopathy
Table 8: Diabetic Retinopathy Patient Prevalence in the US by Diabetes Type: 2006-2015 (In Thousand Patients) (includes corresponding Graph/Chart)
Table 9: Diabetic Retinopathy Patient Prevalence in the US by Age Group: 2006-2012 (includes corresponding Graph/Chart)
Table 10: Diabetic Retinopathy Prevalence in Type-1 Diabetic Patients in the US by Age Group: 2006-2012 (includes corresponding Graph/Chart)
RNAi in Drug Therapeutics
RNAi: Select Targeted Clinical Areas
Age Related Macular Degeneration: A Key Clinical Area of Focus
Select Promising RNAi Drugs in Pipeline: A Review
ALN-VSP
Atu027
CALAA-01
CEQ501
RNAi Therapeutics: Challenges in a Nutshell
Drug Delivery: A Key Challenge Facing RNAi-based Therapeutics
Select Methods of Systemic Drug Delivery under Development
Select RNAi Drug Delivery Technologies under Development
Other Challenges Facing RNAi-based Therapeutics
A Snapshot of Select RNAi Delivery Platforms Under Development
RXi Obtains Exclusive Licensing Rights to Advirna's Delivery Technologies
Dicerna Collaborates with Archemix
Alnylam Collaborates with GSK to Donate Several RNAi Technology Patents
AstraZeneca and Cenix Extend Research Agreement on RNA Interference
Allergan Stops Development of AGN-745 Treatment
Tekmira Inks Agreement with Roche
MDRNA Inks Licensing Agreement with Novartis
MDRNA Inks Agreement with Roche for Developing RNAi Therapeutics
Mirna Therapeutics to Investigate Therapeutic Potential of miRNA
Cenix and Boehringer Ingelheim Ink Research Agreement
Mirna and M. D. Anderson to Explore miRNA Therapeutics in Prostate Cancer
Cubist Partners with Alnylam Pharmaceuticals
Liquidia to License Certain Rights of PRINT technology to Abbott
9. STRATEGIC CORPORATE DEVELOPMENTS - A HISTORIC PERSPECTIVE BUILDER
Invitrogen Merges with Applied Biosystems
MDRNA Obtains Rights to RiboTask's UNA Technology
Roche Takes Over Mirus
Thermo Fischer Snaps Up Open Biosystems
Protiva and Tekmira Complete the Merger of Business Operations
Takeda and Alnylam Enter into Strategic Alliance
SR Pharma Plc. is Now Silence Therapeutics Plc.
10. FOCUS ON SELECT GLOBAL PLAYERS
Alnylam Pharmaceuticals, Inc. (USA)
Benitec Limited (Australia)
Bioneer Corp. (Korea)
Calando Pharmaceuticals, Inc. (USA)
Cenix BioScience GmbH (Germany)
Devgen NV (Belgium)
Dharmacon, Inc. (USA)
Dicerna Pharmaceuticals, Inc. (USA)
Exiqon A/S (Denmark)
Genesis Research & Development Corporation Limited (New Zealand)
Halo-Bio RNAi Therapeutics, Inc. (USA)
Marina Biotech, Inc. (USA)
OPKO Health, Inc. (USA)
Polyplus-transfection SA (France)
Quark Pharmaceuticals, Inc. (USA)
Galena Biopharma (USA)
Sigma-Aldrich Co. (USA)
Silence Therapeutics (UK)
Tekmira Pharmaceuticals Corp. (Canada)
11. GLOBAL MARKET PERSPECTIVE
Table 11: World Recent Past, Current & Future Analysis for RNA Interference by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 12: World Historic Review for RNA Interference by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 13: World 15-Year Perspective for RNA Interference by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, and Rest of World for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)
Table 14: World Recent Past, Current & Future Analysis for RNA Interference in Drug Discovery and Target Validation Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 15: World Historic Review for RNA Interference in Drug Discovery and Target Validation Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 16: World 15-Year Perspective for RNA Interference in Drug Discovery and Target Validation Applications by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, and Rest of World for Years 2003, 2011 & 2017(includes corresponding Graph/Chart)
Table 17: World Recent Past, Current & Future Analysis for RNA Interference Reagents by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 18: World Historic Review for RNA Interference Reagents by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 19: World 15-Year Perspective for RNA Interference Reagents by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, and Rest of World for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)
Table 20: World Recent Past, Current & Future Analysis for siRNA Synthesis by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart)
Table 21: World Historic Review for siRNA Synthesis by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 22: World 15-Year Perspective for siRNA Synthesis by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, and Rest of World for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)
III. MARKET
1. THE UNITED STATES
A. Market Analysis
Outlook
Technological Innovations
Strategic Corporate Developments
Focus on Select Major Players
B. Market Analytics
Table 23: The US Recent Past, Current & Future Analysis for RNA Interference Market by Application Area - Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 24: The US Historic Review for RNA Interference Market by Application Area - Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 25: The US 15-Year Perspective for RNA Interference Market by Application Area - Percentage Breakdown of Dollar Sales for Drug Discovery and Target Validation, Reagents, and siRNA Synthesis for Years 2003, 2011 & 2017(includes corresponding Graph/Chart)
2. CANADA
A. Market Analysis
Strategic Corporate Development
Focus on Select Major Player
B. Market Analytics
Table 26: Canadian Recent Past, Current & Future Analysis for RNA Interference Market by Application Area - Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 27: Canadian Historic Review for RNA Interference Market by Application Area - Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 28: Canadian 15-Year Perspective for RNA Interference Market by Application Area - Percentage Breakdown of Dollar Sales for Drug Discovery and Target Validation, Reagents, and siRNA Synthesis for Years 2003, 2011 & 2017(includes corresponding Graph/Chart)
3. JAPAN
A. Market Analysis
Strategic Corporate Developments
B. Market Analytics
Table 29: Japanese Recent Past, Current & Future Analysis for RNA Interference Market by Application Area - Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 30: Japanese Historic Review for RNA Interference Market by Application Area - Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 31: Japanese 15-Year Perspective for RNA Interference Market by Application Area - Percentage Breakdown of Dollar Sales for Drug Discovery and Target Validation, Reagents, and siRNA Synthesis for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)
4. EUROPE
Market Analytics
Table 32: European Recent Past, Current & Future Analysis for RNA Interference Market by Geographic Region - France, Germany, Italy, UK, and Rest of European Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 33: European Historic Review for RNA Interference by Geographic Region - France, Germany, Italy, UK, and Rest of European Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 34: European 15-Year Perspective for RNA Interference by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, and Rest of European for Years 2003, 2011 & 2017(includes corresponding Graph/Chart)
Table 35: European Recent Past, Current & Future Analysis for RNA Interference Market by Application Area - Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 36: European Historic Review for RNA Interference Market by Application Area - Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 37: European 15-Year Perspective for RNA Interference Market by Application Area - Percentage Breakdown of Dollar Sales for Drug Discovery and Target Validation, Reagents, and siRNA Synthesis for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)
4a. FRANCE
A. Market Analysis
Technological Innovation
Strategic Corporate Development
Focus on Select Major Player
B. Market Analytics
Table 38: French Recent Past, Current & Future Analysis for RNA Interference Market by Application Area - Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 39: French Historic Review for RNA Interference Market by Application Area - Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 40: French 15-Year Perspective for RNA Interference Market by Application Area - Percentage Breakdown of Dollar Sales for Drug Discovery and Target Validation, Reagents, and siRNA Synthesis for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)
4b. GERMANY
A. Market Analysis
Strategic Corporate Developments
B. Market Analytics
Table 41: German Recent Past, Current & Future Analysis for RNA Interference Market by Application Area - Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart)
Table 42: German Historic Review for RNA Interference Market by Application Area - Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 43: German 15-Year Perspective for RNA Interference Market by Application Area - Percentage Breakdown of Dollar Sales for Drug Discovery and Target Validation, Reagents, and siRNA Synthesis for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)
4c. ITALY
Market Analytics
Table 44: Italian Recent Past, Current & Future Analysis for RNA Interference Market by Application Area - Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 45: Italian Historic Review for RNA Interference Market by Application Area - Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 46: Italian 15-Year Perspective for RNA Interference Market by Application Area - Percentage Breakdown of Dollar Sales for Drug Discovery and Target Validation, Reagents, and siRNA Synthesis for Years 2003, 2011 & 2017(includes corresponding Graph/Chart)
4d. THE UNITED KINGDOM
A. Market Analysis
Technological Innovations
Focus on Select Major Player
B. Market Analytics
Table 47: The UK Recent Past, Current & Future Analysis for RNA Interference Market by Application Area - Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 48: The UK Historic Review for RNA Interference Market by Application Area - Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 49: The UK 15-Year Perspective for RNA Interference Market by Application Area - Percentage Breakdown of Dollar Sales for Drug Discovery and Target Validation, Reagents, and siRNA Synthesis for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)
4e. REST OF EUROPE
A. Market Analysis
Strategic Corporate Developments
Focus on Select Major Players
B. Market Analytics
Table 50: Rest of European Recent Past, Current & Future Analysis for RNA Interference Market by Application Area - Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 51: Rest of European Historic Review for RNA Interference Market by Application Area - Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 52: Rest of European 15-Year Perspective for RNA Interference Market by Application Area - Percentage Breakdown of Dollar Sales for Drug Discovery and Target Validation, Reagents, and siRNA Synthesis for Years 2003, 2011 & 2017(includes corresponding Graph/Chart)
5. ASIA-PACIFIC
A. Market Analysis
Strategic Corporate Developments
Focus on Select Major Players
B. Market Analytics
Table 53: Asia-Pacific Recent Past, Current & Future Analysis for RNA Interference Market by Application Area - Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently nalyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 54: Asia-Pacific Historic Review for RNA Interference Market by Application Area - Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 55: Asia-Pacific 15-Year Perspective for RNA Interference Market by Application Area - Percentage Breakdown of Dollar Sales for Drug Discovery and Target Validation, Reagents, and siRNA Synthesis for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)
6. REST OF WORLD
Market Analytics
Table 56: Rest of World Recent Past, Current & Future Analysis for RNA Interference Market by Application Area - Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 57: Rest of World Historic Review for RNA Interference Market by Application Area - Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 58: Rest of World 15-Year Perspective for RNA Interference Market by Application Area - Percentage Breakdown of Dollar Sales for Drug Discovery and Target Validation, Reagents, and siRNA Synthesis for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)
IV. COMPETITIVE LANDSCAPE
RNA Interference (RNAi) published by Global Industry Analysts, Inc. in April 1, 2012. This report consists of Pages: 792 and the price starts from US $ 4800.
The contents of this page may be different from the latest version. Please contact us for details.
